Related Experiment Video

Updated: May 23, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Tyrosine kinase inhibitors in lung cancer

Anish Thomas1, Arun Rajan, Giuseppe Giaccone

  • 1Medical Oncology Branch, National Cancer Institution, Room 12N226, 10 Center Drive, Bethesda, MD 20892, USA.

Hematology/Oncology Clinics of North America
|April 24, 2012
PubMed

Insights

Targeted therapies like tyrosine kinase inhibitors (TKIs) are revolutionizing cancer treatment, particularly for lung cancer. This review covers clinical data and management strategies for epidermal growth factor receptor and anaplastic lymphoma kinase TKIs.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Driver mutations in protein kinases, especially tyrosine kinases, are key targets in cancer therapy.
  • Tyrosine kinase inhibitors (TKIs) have emerged as effective treatments for various malignancies, including lung cancer.

Purpose of the Study:

  • To review the clinical data supporting the use of TKIs in cancer treatment.
  • To discuss practical aspects of managing patients receiving TKIs, focusing on specific targets.

Main Methods:

  • Literature review of clinical trials and studies on TKIs.
  • Analysis of resistance mechanisms and strategies to overcome them.
  • Discussion of patient management in the context of targeted therapy.

Main Results:

  • Identification of driver mutations has accelerated TKI drug development.
  • Improved understanding of TKI biology aids in overcoming resistance.
  • Clinical data supports the efficacy of specific TKIs in lung cancer.

Conclusions:

  • TKIs targeting epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) have shown significant clinical benefit.
  • Effective patient management strategies are crucial for optimizing TKI therapy and overcoming resistance.

More Related Videos

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...